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Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5mg to diabetic macular edema (DME)
patients, prior to reimbursement.Methods. Open-label, prospective, phase IIIb study.Majority of patients were not treatment-na¨ıve
before enrollment. Patients received ranibizumab as per the EU label (2011). Safety was assessed by incidences of ocular/systemic
adverse events (AEs) and serious AEs (SAEs) and e'cacy in terms of visual acuity (VA) change from baseline (decimal score or
Snellen (20/value)). Results. Overall, 515 patients (83.5%) completed the study. In unilateral/bilateral patients, commonly observed
AEs were cardiac disorders (1.3%/1.3%) and nervous system disorders (1.3%/1.1%); SAEs were reported in 4.5%/4.8% of patients.
Acute renal failure, lung carcinoma, and cardiac arrest were the causes of death in one unilateral and two bilateral patients.
Ranibizumab improved/maintainedVA (Snellen (20/value)/decimal scores) in both unilateral (up to−16.7/1.5) and bilateral patients
(up to −23.6/1.2) at Month 5, with a mean of 4.15 and 4.40 injections, respectively. Overall, no di,erence was observed in the VA
outcomes and treatment exposure between unilateral/bilateral patients. Conclusions.&e PRIDE study provided early ranibizumab
access to >600 Italian patients. Ranibizumab was well-tolerated and improved/maintained VA in 40.2%–68.8% patients, with no
di,erences in case of unilateral or bilateral pathology.&e study is registered with EudraCT.
1. Introduction
Diabetic macular edema (DME) is one of the leading causes
of visual impairment in the working-age population in
developed countries [1]. Clinical trials data from Europe
and the United States indicate that, of the total diabetic
population, 7%–12%su,er fromDMEand 1%–3%have visual
impairment due to DME [2]. &e World Health Organiza-
tion (WHO) estimates that the number of Europeans with
diabetes is expected to increase from 33 million (4 million
in Italy) in 2000 to 48 million (5 million in Italy) in 2030,
with a likely corresponding increase in the prevalence of
visual impairment due to DME [3].&erefore, in addition to
systemic control of diabetes, identifying treatment strategies
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to e,ectively manage patients with DME is imperative. In
Italy, there is currently no data available on the prevalence
and incidence of legal blindness (residual vision 1/20 (20/400
feet, 6/120 meters) or lower for both the eyes) in patients
with diabetes [4]. Epidemiological data from Italy show that
at least 30% of patients with diabetes su,er from retinopathy
and that every year 1% of patients with diabetes are a,ected
by the most severe forms of retinopathy [5].
In the past, treatment options for DME were limited to
laser photocoagulation, triamcinolone intravitreal injections,
and vitrectomy [6–8]. Most of these target the prevention of
vision loss and result in limited visual acuity (VA) improve-
ments, while causing safety concerns such as foveal burns,
visual -eld defects, retinal -brosis, and laser scars [9].
Of the antivascular endothelial growth factors (VEGF)
that are currently being used or investigated for ophthalmic
conditions, ranibizumab (Lucentis; Novartis Pharma AG,
Basel, Switzerland, and Genentech Inc., South San Francisco,
CA) was the -rst VEGF inhibitor approved by the Com-
mittee for Medicinal Products for Human Use (CHMP),
for the treatment of DME. Ranibizumab is a humanized
monoclonal antibody Fab fragment (without the Fc portion)
speci-cally designed for ocular use. It binds to VEGF-A with
high a'nity and inhibits all the isoforms of VEGF-A [10].
Data for treatment of DME with ranibizumab are based on
prospective phases II and III randomized clinical studies,
including READ-2, RESOLVE, RISE & RIDE, RESTORE,
RESTORE extension, DRCR.net (Protocol I), REVEAL, and
LRT (NCT00444600) [11–20]. Ranibizumab 0.5mg pro re
nata (PRN) was identi-ed as the new standard of care follow-
ing the conclusion of the RESOLVE [16] and RESTORE [11]
studies. At 12months, these studies showed that ranibizumab
pooled group (RESOLVE; 0.3mg–0.6mg and 0.5mg–1.0mg)
and ranibizumab 0.5mg pro re nata (RESTORE) provided
superior VA gains compared with controls (RESOLVE, 10.3
versus −1.4 with sham control, 푝 < 0.0001; RESTORE
6.8 versus 0.9 with laser control, 푝 < 0.0001) [21]. Long-
term data from the 2- and 3-year RESTORE extension [17,
18] and DRCR.net (Protocol I) [13, 14] studies, respectively,
demonstrated that individualized ranibizumab 0.5mg dosing
maintained the initial BCVA improvement observed at Year
1 through Years 2 and 3, with lower number of injections. In
order to provide early access to ranibizumab for patients with
no therapeutic alternative other than laser, Novartis Farma
S.p.A initiated an expanded access program (EAP) in Italy
(the PRIDE study) in 2011. Ranibizumab was administered
to the patients according to the then approved label until
reimbursement for DME indication and was available at the
referral center according to the Hospital Formulary System
(Prontuario Terapeutico Ospedaliero (PTO)/Prontuario Ter-
apeutico Ospedaliero Regionale (PTOR)) requirements.&is
EAP provided the opportunity to evaluate the safety and
e'cacy of ranibizumab in Italian patients with DME akin
to the real-world/routine clinical practice. Additionally, most
of the DME patients (over 90%) included in the study were
not treatment-naı¨ve prior to study enrollment.&e study also
analyzed the e'cacy in patients with very poor vision (best-
corrected visual acuity (BCVA) <20/320), who are typically
excluded from clinical trials. Here, we present the 18-month
results from the PRIDE study.
2. Materials and Methods
2.1. Study Design. PRIDE was a phase IIIb, open-label EAP
studywith amaximumof 18months of follow-upperiod, con-
ducted in 33 centers in Italy from November 7, 2011, to Octo-
ber 8, 2013, in patients with visual impairment due to DME
(unilateral and bilateral). Informed consent was obtained
from each patient in writing at screening, before any data
were collected or procedure was performed. &e study was
conducted in accordance with the Declaration of Helsinki
and approval was obtained from the Independent Ethics
Committee or Institutional Review Board in all the centers.
&e study is registered with https://eudract.ema.europa.eu/
(2011-002731-26).
2.2. Patients. &e study enrolled 617 patients, ≥18 years of
age with either Type I or Type II diabetes mellitus according
to the American Diabetes Association or WHO guidelines
and visual impairment due to focal/di,use DME in at least
one eye for which no suitable therapeutic alternatives existed.
&e study included patients with both unilateral DME and
bilateral DME; if both eyes were eligible, the one with the
worst VA, as assessed at visit 1, was selected for treatment in
patients with bilateral DMEunless, based onmedical reasons,
the investigator deemed the other eye more appropriate for
treatment (similar to the RESTORE study) [11]. Patients
were excluded if they had a history of uveitis in either eye,
uncontrolled glaucoma in either eye (intraocular pressure
(IOP) >30mmHg on medication or according to the investi-
gator’s judgment), evidence of either vitreomacular traction
(in either eye) or active proliferative diabetic retinopathy
(study eye), usage of intravitreal antiangiogenic drugs within
1month before enrollment, pan retinal laser in the study eye
within 6 months before enrollment, focal/grid laser in the
study eyewithin 3months before enrollment, or hypertension
uncontrolled by medication.
2.3. Study Objectives. &e objective of the study was to
provide an early access to ranibizumab for patients with
visual impairment due to DME for whom no suitable
therapeutic alternatives existed (i.e., existing therapies, e.g.,
laser photocoagulation, have failed or were not indicated)
and to generate safety data of ranibizumab 0.5mg treatment
(administered according to the European Union Summary of
Product Characteristics (EU SmPC) label, 2011) in an Italian
population that resembles future clinical practice.
In our study, we analyzed the dataset seeking a di,erence
between unilateral versus bilateral pathology in patients with
DME; however, only unilateral treatment (one study eye) was
allowed.
2.4. Treatment. Enrolled patients received intravitreal rani-
bizumab 0.5mg injections as per the then approved rani-
bizumab EU SmPC label, 2011. Initially, three consecutive
monthly doses of ranibizumab 0.5mg were administered
until the maximumVAwas achieved.&e treatment was sus-
pendedupon stabilization of vision, that is, when therewas no
further improvement in BCVA attributable to ranibizumab
treatment for two consecutive visits. Patients were monitored
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monthly, and if a decrease in VA due to disease activity was
observed,monthly ranibizumab treatment was resumed until
VA was stable for 3 consecutive monthly assessments. All
patients were eligible to receive laser treatment at aminimum
interval of 90 days according to the Early Treatment Diabetic
Retinopathy Study (ETDRS) guidelines at the investigators’
discretion (recorded as concomitant medication). If both
ranibizumab and laser were given on the same day, then
ranibizumab was administered at least 30minutes a/er laser
treatment.
2.5. Assessments
2.5.1. Treatment Exposure. &e proportion of patients receiv-
ing an injection at each visit, as well as the total number
of injections administered from baseline to the end of the
study (i.e., maximum until Month 18), and the number of
visits, during which injections could be administered, were
computed and described by the means of usual descriptive
statistics. In addition, the ratio between the total number of
injections performed and the number of visits during which
ranibizumab could be administered was determined. &e
number of patients with at least one study drug interruption
was also calculated. Time to -rst retreatment, de-ned as the
time elapsed (in days) from the last performed injectionwhen
VA reached stability to the date of-rst injection following-rst
treatment interruption, was computed.
2.5.2. Safety. Safety was assessed by the incidence of ocular
and systemic adverse events (AEs) and serious adverse
events (SAEs), standard ophthalmic examinations and IOP
measurements, and so forth.&e incidence of AEs and SAEs
based on the standardizedMedical Dictionary for Regulatory
Activities was summarized by the primary system organ class
(SOC) and preferred term.
2.5.3. E-cacy. &e total VA was assessed at all scheduled
visits using the Snellen VA charts (i.e., evaluations expressed
in Snellen 20/value fraction and as decimal scores). E'cacy
outcomes are presented in terms of total VA change from
baseline (the Snellen scale and decimal scores) and in terms
of proportion of patients with improvement, worsening, or
no change in total VA at every study visit in the -rst 6months
of the treatment. Moreover, the e'cacy was also assessed in
the subgroup of patients (i) who were monocular or had a
BCVA score of ≤24 letters (approximately <20/320 Snellen
equivalent) in the fellow eye and (ii) with at least 6 months
of follow-up.
2.6. Statistical Analysis. &e safety analysis was conducted
on the safety set. It consisted of all patients who received
at least one dose of ranibizumab and had undergone at
least one postbaseline safety assessment.&e e'cacy analysis
was conducted on the per protocol population as well as in
the following subgroups: patients with at least 6 months of
follow-up and in patients who were monocular or with VA<20/320 Snellen in the fellow eye. Changes of total VA versus
baseline were calculated in categorical terms. (i) Using the
Snellen scale, “improvement” was de-ned as a decrease in
Table 1: Baseline demographic and disease characteristics.
Characteristics Unilateral DME(푛 = 157) Bilateral DME(푛 = 455)
Age, mean ± SD, years 66.36 ± 9.1 64.69 ± 9.2
Male (푛%) 60.51 63.74
Caucasians (푛%) 100 99.34
Baseline BCVA, mean ± SD
Decimal score (value/10) 3.98 ± 2.24 3.56 ± 2.03
Snellen (20/value) 82.13 ± 84.71 91.95 ± 142.00
Age at -rst DME diagnosis,
mean ± SD, years 63.84 ± 9.34 61.65 ± 9.23
Time from DME diagnosis to
study entry, mean ± SD, years 2.57 ± 3.35 3.26 ± 3.11
BCVA, best-corrected visual acuity; DME, diabetic macular edema; SD,
standard deviation.
the total VA fraction denominator at the considered visit
versus baseline, “no change” was de-ned as no di,erence
in the total VA fraction denominator at the considered visit
versus baseline, and “worsening” was de-ned as an increase
in the total VA fraction denominator at the considered visit
versus baseline. (ii) Using the decimal score, “improvement”
was de-ned as an increase of the considered visit fraction
versus baseline, “no change” was de-ned as no di,erence in
the considered visit fraction versus baseline, and “worsening”
was de-ned as a decrease of the considered visit fraction ver-
sus baseline. Data were summarized using frequency counts
and percentage for categorical variables, mean, median,
least square (LS) mean, standard deviation (SD), standard
error (SE), and min-max values for continuous variables. A
Wilcoxon signed rank sum test to evaluate (with descriptive
meanings only) the statistical signi-cance of VA change at 6
months versus baselinewas performed for both unilateral and
bilateral patients with DME.
3. Results
3.1. Patient Disposition and Baseline Characteristics. A total
of 617 patients were enrolled into the study, of which 612
received at least one dose of the study treatment (safety set).
&e baseline demographic and disease characteristics were
generally well-balanced among the unilateral (푛 = 157) and
bilateral (푛 = 455) patients with DME (Table 1).
A total of 515 (83.5%) patients completed the study
(Figure 1). Overall, 102 of the 617 enrolled patients discon-
tinued the study before the program’s closure. &e main
reasons for discontinuation were consent withdrawal (32,
5.2%), patients lost to follow-up (27, 4.4%), and AEs (19,
3.1%). Notably, 56 (9.1%) of the total enrolled patients had
ocular disorders in the study eye that could confound the
interpretation of results, compromise VA, or require medical
or surgical intervention during the study period. &e ocular
disorders in such patients included cataract, retinal vascular
occlusion, retinal detachment, macular hole, or choroidal
neovascularization of any cause (e.g., age-related macular
degeneration, ocular histoplasmosis, or pathologic myopia).
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Unilateral DME (n = 158)
27 discontinued from the study due to the
following reasons:
(i) Adverse events: 7
(ii) Abnormal test procedure: 0
(iii) Unsatisfactory therapeutic e!ect: 1
(iv) Patient’s condition no longer required
study drug: 1
(v) Protocol violation: 1
(vi) Patients withdrew consent: 7
75 discontinued from the study due to the
following reasons:
(i) Adverse events: 12
(ii) Abnormal test procedure: 1
(iii) Unsatisfactory therapeutic e!ect: 7
(iv) Patient’s condition no longer required
study drug: 3
(v) Protocol violation: 7
(vi) Patients withdrew consent: 25
(vii) Loss to follow-up: 18
(viii) Death: 2
(vii) Loss to follow-up: 9
(viii) Death: 1
Bilateral DME (n = 459)
Patients with DME enrolled (N = 617)
Completed (n = 131) Completed (n = 384)
Figure 1: Patient disposition.
In addition, 18 (3%) patients received laser treatment in
the study eye during the study (reported as protocol devi-
ations). About 143 (31.4%) bilateral DME patients and 41
(26.1%) unilateral DME patients had received bevacizumab
treatment (for nonocular conditions); 7 (1.5%) bilateral DME
patients and 1 (0.6%) unilateral DME patient had received
ranibizumab treatment prior to study enrollment while 1
(0.22%) patient with bilateral DME had received dexametha-
sone treatment prior to study enrollment.
3.2. Treatment Exposure
3.2.1. Average Number of Injections. On average, the study
eye of unilateral and bilateral patients with DME received a
mean (median) of 4.15 (4.00) and 4.40 (4.00) ranibizumab
injections, respectively (Table 2), with 7 visits on average over
the -rst 6months of follow-up. Most patients received 2 to 6
injections. A majority of patients received injections in the
range of 2 to 5 (interquartile range: 3–5) for unilateral DME
(77.0%) and in the range of 3 to 6 (interquartile range: 3–6)
injections for bilateral DME (70.8%).&e ratio of number of
injections to the number of visits was, on average, 0.62 ± 0.18
for unilateral and 0.65 ± 0.19 for bilateral DME eyes.
In the subgroup of patients with at least 6 months of
follow-up, themedian number of injections was 4 (interquar-
tile range: 3–5) in patients with unilateral DME and 5
(interquartile range: 4-5) in patients with bilateral DME.
3.2.2. Treatment Interruption. Overall, 86.6% (푛 = 136/157)
of the unilateral and 87.7% (푛 = 399/455) of the bilateral
patients achieved stable ocular condition at least once during
the study that could last for more than one visit and hence
suspended ranibizumab treatment.&e number of visits dur-
ing which injections were not performed for these patients
Table 2: Number of ranibizumab treatments received during the 18-
month follow-up period.
Unilateral DME
(푛 = 157) Bilateral DME(푛 = 455)
Number of injections, mean ± SD 4.15 ± 1.99 4.40 ± 2.11
Number of visits, mean ± SD 7.15 ± 3.57 7.09 ± 3.41
Number of injections/number of
visits ratio, mean ± SD 0.62 ± 0.18 0.65 ± 0.19
DME, diabetic macular edema; SD, standard deviation.
was, on an average, 3.22 ± 2.45 (unilateral) and 2.83 ± 2.27
(bilateral; ranges for both: 1–12) over the 18-month follow-up
period.
In the subgroup of patients with at least 6 months
of follow-up, the proportion of patients who discontinued
treatment due to stable ocular condition at any visit from
baseline to Month 6 were 82.4% in the unilateral group and
75.3% in the bilateral group.
3.2.3. Retreatment. Retreatment was de-ned as reinitiation
of injections a/er the interruption of ranibizumab treatment.
A total of 28.7% (푛 = 39/136) of the unilateral and 26.8%
(푛 = 107/399) of the bilateral patients resumed ranibizumab
treatment at least once a/er having reached VA stability.
Time to -rst retreatment (LS mean ± SE) was, on an average,160.37 ± 7.16 (unilateral) and 175.17 ± 5.93 (bilateral) days.
&e di,erences between unilateral and bilateral DME were
not statistically signi-cant as determined by the log-rank test.
In the subgroup of patients with at least 6 months of
follow-up, time to retreatment (LS mean ± SE) was 102.28 ±2.79 (unilateral) and 102.39 ± 2.21 (bilateral) days.
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Table 3: Incidences of SAEs during the 18-month follow-up period (safety set).
Preferred term, 푛 (%) Unilateral DME(푛 = 157) Bilateral DME(푛 = 455)
Any SAE 7 (4.46) 22 (4.84)
Cardiac disorders 2 (1.27) 6 (1.32)
Acute myocardial infarction 0 1 (0.22)
Atrial 8utter 1 (0.64) 0
Cardiac arrest 0 1 (0.22)
Cardiac failure 0 3 (0.66)
Cardiopulmonary failure 0 1 (0.22)
Congestive cardiomyopathy 1 (0.64) 0
Ischemic cardiomyopathy 0 1 (0.22)
Myocardial ischemia 1 (0.64) 0
Eye disorders 0 2 (0.44)
General disorders and administration site conditions 0 1 (0.22)
Infections and infestations 0 3 (0.66)
Injury, poisoning, and procedural complications 0 2 (0.44)
Metabolism and nutrition disorders 0 1 (0.22)
Musculoskeletal and connective tissue disorders 0 1 (0.22)
Neoplasms benign, malignant, and unspeci-ed (including cysts and polyps) 1 (0.64) 3 (0.66)
Nervous system disorders 2 (1.27) 3 (0.66)
Renal and urinary disorders 1 (0.64) 1 (0.22)
Respiratory, thoracic, and mediastinal disorders 1 (0.64) 1 (0.22)
Surgical and medical procedures 0 1 (0.22)
Vascular disorders 1 (0.64) 1 (0.22)
DME, diabetic macular edema; SAE, serious adverse event.
3.3. Safety
3.3.1. SAEs and Deaths. SAEs were reported in 7 (4.5%)
patients with unilateral DME and 22 (4.8%) patients with
bilateral DME. One case of ocular hypertension was clas-
si-ed as an SAE that was not suspected to be related to
ranibizumab (Table 3). Cardiac disorders were the most
frequently observed SAEs in unilateral (2 (1.3%)) and bilateral
(6 (1.3%)) patients with DME. Ischemic stroke, hypertension,
and ischemic cardiomyopathy (1 each, 0.2%) in bilateral
DME were suspected to be related to the study drug. One
(0.6%) patient with unilateral DME and 2 (0.4%) patients
with bilateral DME died during the study due to acute renal
failure, lung carcinoma, and cardiac arrest; none of themwere
considered to be related to ranibizumab treatment.
3.3.2. Adverse Events. &e occurrence of one or more AEs
was reported in 12 (7.6%) patients with unilateral DME and
49 (10.8%) patients with bilateral DME. &e percentages of
patients with at least one ocular AE were 5 (3.2%) and 19
(4.2%) among the unilateral and bilateral DME patients.&e
proportions of patients with systemic AEs were 7 (4.5%) and
36 (8.0%) in unilateral and bilateral patients, respectively.
Among patients with unilateral and bilateral DME, eye
disorders (5 (3.2%) and 19 (4.2%)), cardiac disorders (2
(1.3%) and 6 (1.3%)), and nervous system disorders (2 (1.3%)
and 5 (1.1%)) were the most frequently observed SOC. &e
nonocular AEs of infections and infestations were observed
only in patients with bilateral DME (8 (1.8%); Table 4).
As assessed by the investigator, the AEs suspected to be
related to ranibizumab treatment were reported in 1 (0.6%)
patient with unilateral DME and 7 (1.5%) patients with
bilateral DME. In the patient with unilateral DME, these
AEs were categorized as ocular hypertension and cataract. In
patients with bilateral DME, 3 patients reported eye disorders
suspected to be related to the study drug, 2 categorized
with the cataract (0.4%), and the other one with increased
lacrimation (0.2%).
&e other AEs possibly related to study drug were
ischemic stroke (SAE), hypertension (SAE), ischemic car-
diomyopathy (SAE), microalbuminuria, and IOP increase.
3.3.3. AEs Leading to Discontinuation. Eight patients (5.1%)
with unilateral DME and 14 (3.1%) patients with bilateral
DMEdiscontinued the study due toAEs. In patients with uni-
lateral and bilateral DME, cardiac disorders (2 (1.3%) and 4
(0.9%)) and nervous system disorders (2 (1.3%) and 3 (0.7%))
were the most frequent AEs leading to discontinuation. Two
(0.4%) patients with bilateral DME and 1 (0.6%) patient
with unilateral DME discontinued for events categorized as
vascular disorders (arterial disorder in unilateral DME and
hypertension and hypertensive crisis in bilateral DME).
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Table 4: Incidences of AEs during the 18-month follow-up period (safety set).
Preferred term, 푛 (%) Unilateral DME(푛 = 157) Bilateral DME(푛 = 455)
Any AE 12 (7.64) 49 (10.77)
Blood and lymphatic system disorders 0 1 (0.22)
Cardiac disorders 2 (1.27) 6 (1.32)
Eye disorders (mainly cataract, conjunctival hemorrhage, and diabetic retinal edema being the major) 5 (3.18) 19 (4.18)
General disorders and administration site conditions 0 2 (0.44)
Infections and infestations 0 8 (1.76)
Injury, poisoning, and procedural complications 0 3 (0.66)
Investigations 0 1 (0.22)
Metabolism and nutrition disorders 0 1 (0.22)
Musculoskeletal and connective tissue disorders 0 1 (0.22)
Neoplasms benign, malignant, and unspeci-ed (including cysts and polyps) 1 (0.64) 4 (0.88)
Nervous system disorders 2 (1.27) 5 (1.10)
Psychiatric disorders 0 1 (0.22)
Renal and urinary disorders 1 (0.64) 2 (0.44)
Respiratory, thoracic, and mediastinal disorders 1 (0.64) 1 (0.22)
Skin and subcutaneous tissue disorders 0 1 (0.22)
Surgical and medical procedures 0 4 (0.88)
Vascular disorders 1 (0.64) 3 (0.66)
AE, adverse event; DME, diabetic macular edema.
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Figure 2: Total VA change (treated eye) from baseline during the 18-month follow-up period in (a) decimal score and in (b) Snellen 20/value,
in both unilateral and bilateral patients with DME (per protocol population). Note: the VA loss (in decimal and Snellen scores) at Month 14
was due to treatment interruptions at Month 12 and Month 13 because of ocular stability. Patients were again treated at Month 14 and this led
to an increase in VA response at Month 15; BSL, baseline; DME, diabetic macular edema; VA, visual acuity.
3.4. E-cacy. Patients recruited in the study had no thera-
peutic alternative; over 90% of the patients received mainly
laser and/or bevacizumab prior to study enrollment and,
hence, were not treatment-naı¨ve. Overall, treatment with
ranibizumab helped either improve or maintain VA of the
treated eye in patientswith both unilateral and bilateralDME.
&e mean baseline VA (in Snellen (20/value)/decimal score)
was 73.17/4.11 and 88.02/3.72 in patients with unilateral and
bilateral DME, respectively. &e Snellen fraction denomi-
nators of total VA measured on the treated eye tended to
decrease during the study in unilateral and bilateral DME
patients, by amean (± SD) of−16.7±37.84 and−23.62±40.51
Snellen (20/value) compared with baseline VA. In terms of
decimal score, the mean (±SD) VA gain in unilateral and
bilateral patients was 1.5 ± 2.38 and 1.22 ± 1.67 at Month
5, respectively, compared with baseline VA (Figure 2). &e
VA loss (in decimal and Snellen scores) at Month 14 was
due to treatment interruptions at Month 12 and Month 13
because of ocular stability (the patient’s VA was stable for
two consecutive monthly assessments). Patients were treated
again at Month 14 which led to an increase in VA response at
Month 15.
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Figure 3: Proportion of patients with total VA (Snellen) improvement, no change, or worsening in patients with at least 6months of follow-
up, in both (a) unilateral and (b) bilateral patients with DME. “Improvement” was de-ned as a decrease in the total visual acuity fraction
denominator at considered visit versus baseline, “no change” as no di,erence in the total visual acuity fraction denominator at considered
visit versus baseline, and “worsening” as an increase in the total visual acuity fraction denominator at considered visit versus baseline. DME,
diabetic macular edema; VA, visual acuity.
3.4.1. Proportion of Patients with Improvement, Worsening,
or No Change in VA at Each Visit in the First 6 Months of
Follow-Up. &e percentage of “improvement” in VA through
visits was found to be higher than that of “worsening” and
“no change” for both unilateral (61.2% (improvement) versus
10.2% (worsening) and 24.5% (no change)) and bilateral
patients (68.8%(improvement) versus 16.8%(worsening) and
13.6% (no change)) with DME. &e proportion of unilateral
patients with a total VA improvement increased from 40.2%
at Month 1 to 61.2% over 6months of follow-up. Similarly, in
bilateral patients with DME, the proportion increased from
52.5% to 68.8% fromMonth 1 to Month 6 (Figure 3).
3.5. Subgroups
3.5.1. Patients Who Were Monocular or with BCVA <20/320
Snellen in the Fellow Eye. A decrease in the Snellen fraction
denominators and a gain in the decimal scores were observed
in both unilateral and bilateral patients (up to −27.4 and
0.41 at visit 3 (Month 1) and up to −50.6 and 2.39 at visit
6 (Month 4), resp., considering only the -rst visits involved
the maximum number of patients) when compared with
mean baseline VA (in Snellen (20/value)/decimal score) of
132.09/3.12 and 189.45/2.99 of unilateral and bilateral patients
with DME.
3.5.2. E-cacy Outcome in Patients with at Least 6 Months of
Follow-Up. A total of 254 patients had at least 6 months of
follow-up. Greatest improvement in the median VA change
was observed a/er 3-4 months from the start of the study,
with a decrease in denominators equal to −9 (unilateral) and−12 (bilateral; Figure 4) in terms of Snellen (20/value) and
a gain of 1 decimal score in both unilateral and bilateral
patients with DME.&e Wilcoxon signed ranks tests showed
that the total VA a/er 6 months of follow-up reached a
strong statistical signi-cance (푝 < 0.0001) for both unilateral
and bilateral patients with DME compared with baseline
(Figure 4).
4. Discussion
&e PRIDE study evaluated the outcome of an EAP in Italy
that aimed to provide early access to ranibizumab treatment
for patients with DME who had no therapeutic alternative;
most patients were not na¨ıve to treatment before entering
the study (i.e., received several di,erent treatments including
laser, ranibizumab, and/or bevacizumab). As a result of
this study, 612 patients with DME received ranibizumab
treatment, while reimbursement was under consideration by
the ItalianMedicines Agency (Agenzia Italiana del Farmaco).
A/er reimbursement was granted on December 6, 2012,
cancellation of the PRIDE EAP study resulted in a variable
follow-up period ranging from a minimum of 1 month to
a maximum of 18 months for enrolled patients, with the
majority completing 6months of follow-up in the study.&e
PRIDE study recruited outpatients from 33 centers in Italy
and was largely re8ective of the real-world clinical setting.
Overall, ranibizumab was well-tolerated in the Italian patient
population, with no new ocular or nonocular safety -ndings
during EAP. Ranibizumab treatment either improved or
maintained VA in both unilateral and bilateral patients with
DME.
&e incidence of ocular and nonocular AEs and SAEs
during the study period was low and consistent with those
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Figure 4: Median VA change in the treated eye from baseline in (a) Snellen (20/value) and (b) decimal score in the subgroup with at least 6
months of follow-up in unilateral and bilateral patients with DME. BSL, baseline; DME, diabetic macular edema; VA, visual acuity.
observed in randomized clinical trials of ranibizumab 0.5mg
PRN in patients with visual impairment due to DME [11, 13,
14, 16–18]. One patient with unilateral DME (0.6%) and two
with bilateral DME (0.4%) died during the study primarily
due to acute renal failure, lung carcinoma, and cardiac
arrest. None of the deaths were considered to be related to
ranibizumab treatment.
In the PRIDE study, ranibizumab treatment was based
on the EU SmPC 2011, driven by VA loss [21]. Most patients
received 2–6 injections, with unilateral patients with DME
receiving slightly fewer injections than those with bilateral
DME. In patients who completed 6 months of the follow-
up period, the greatest improvement in median VA change
(Snellen (20/value)) was observed a/er 3-4 months from
the start of the study. &e average number of injections
received by patients in the PRIDE study was comparable to
the recent ranibizumab studies in DME, such as RELIGHT
[22] (≈8 in follow-up period of 18 months; patients received
monthly PRN in-rst 6months andbimonthly PRN treatment
therea/er) and RETAIN [23] (≈10 in 24 months in the PRN
arm) which resulted in a mean change in BCVA of 6.5 letters
(PRN arm), in the RELIGHT study, and 7.44 letters (PRN
arm), in the RETAIN study. &is trend was also observed in
the long-term RESTORE and DRCR.net (Protocol I) studies
which showed that the initial BCVA improvements observed
at Year 1 were maintained through Years 2 and 3 with a
reduced number of injections [11, 13, 14, 17, 18].
&e PRIDE study which is re8ective of real-world data
likewise showed that not all patients required monthly
treatment. &e lower injection numbers and consequent
lower VA outcomes in the PRIDE study may be explained
by the retreatment criteria used in the study. &e current
approved EU SmPC 2014 for ranibizumab addresses the need
for individualized treatment [21]. Flexibility in monitoring
and retreatment allows for a fully personalized treatment
approach. &is includes injecting every month until VA sta-
bilizes; option to extend monitoring by four weekly intervals,
if VA remains stable, for a maximum of 12 weeks; and
retreatment based on VA and/or morphological parameters.
Overall, during the EAP, treatment with ranibizumab
either improved or maintained VA of the treated eye in both
patients with unilateral or bilateral DME. In addition, a sub-
group analysis further corroborated that VA either improved
or was maintained in the majority of patients in this study.
Approximately, 1/2 of the patients demonstrated an initial
VA improvement and achieved stability as early as Months
2-3, with 3-4 ranibizumab injections. Patients were treated
as per the EU SmPC, 2011, which mandated ranibizumab
injections until VA was stable for 3 consecutive months.
Categories of total VA change classi-ed as “improvement,”
“worsening,” or “no change” also showed better e'cacy
outcomeswith ranibizumab treatment in the treated eyes, and
the percentages of improvement through visits were found
to be de-nitively higher than the proportions of “worsening”
and “no change” for both unilateral and bilateral patients with
DME.
Analyses repeated on subgroups of particular interest,
that is, patients who were monocular or with BCVA <20/320
Snellen in the fellow eye and patients who had completed
6 months of the follow-up period, con-rmed the evidence
emerging from the safety and the per-protocol populations.
Ranibizumab injections were associated on average with
VA improvement in the treated eye that reached statistical
signi-cance during 6months of the follow-up period.
&e PRIDE study had certain limitations. About 3% of
the enrolled patients received laser treatment in the study
eye that was reported as a protocol deviation in the study.
Overall, 9% of the enrolled patients had ocular disorders
in the study eye that could confound the interpretation of
results, compromise VA, or required medical or surgical
intervention during the study period (reported as protocol
deviation), possibly in8uencing the VA outcomes. Another
limitation of the study was that the e,ect of pretreatment
with laser (reported as protocol deviation) or anti-VEGFs
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including bevacizumab or ranibizumab that may have an
impact on the overall BCVA outcomes of such patients was
not analyzed separately during the course of the study. Also,
caution needs to be exercised when comparing outcomes of
PRIDE (real-world experience), with the randomized clinical
trials investigating ranibizumab for visual impairment due to
DME.
&e PRIDE study, an EAP, demonstrated that ranibi-
zumab administered according to the EU SmPC, 2011 was
generally well-tolerated and either improved or maintained
VA in patients with DME, despite the fact that more than
90% of the patients were not treatment-naı¨ve. &e current
study adds to the overall real-world clinical experience of
ranibizumab in patients with visual impairment due to DME.
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